VAST: The Science Behind a Triple-Mechanism Sublingual ED Formula

Most erectile dysfunction treatments work through a single mechanism: they inhibit an enzyme in penile smooth muscle to allow blood to accumulate. This approach has been transformative — but it operates entirely at the tissue level, downstream from the neurological events that actually initiate erection. VAST takes a different approach, combining two peripheral vasodilatory agents with a centrally-acting dopamine agonist, all delivered sublingually for accelerated onset. The result is a formulation designed to address erectile response from the brain to the blood vessel simultaneously.

The Neurology of Erection: Why Central Mechanisms Matter

Erection begins in the brain, not the penis. When a man encounters a sexual stimulus — whether visual, tactile, or psychological — a cascade of neural signals originates in limbic and hypothalamic structures and travels down the spinal cord to the pudendal and cavernous nerves. These nerves release nitric oxide, triggering relaxation of smooth muscle in the corpus cavernosum and the arterial dilation that drives engorgement.

The paraventricular nucleus (PVN) of the hypothalamus is a key orchestration site for this process. Neurons in the PVN project directly to both the spinal cord and the brainstem nuclei involved in penile erection. Dopamine receptor stimulation within the PVN — specifically D1, D2, and D4 subtypes — has been shown to potently activate these pro-erectile pathways. This central mechanism operates independently of and additively with the peripheral nitric oxide/cGMP cascade targeted by PDE5 inhibitors.

For men whose ED has a neurological or psychogenic component, peripheral vasodilation alone may not be sufficient. The signal from the brain needs to be strong enough to initiate the cascade in the first place. This is the pharmacological rationale for including a centrally-acting agent alongside peripheral PDE5 inhibitors.

Apomorphine 3mg: The Dopaminergic Trigger

Apomorphine is a non-selective dopamine agonist with affinity for D1, D2, D3, and D4 receptor subtypes. Unlike dopamine itself, apomorphine readily crosses the blood-brain barrier and acts centrally within minutes of sublingual absorption.

Research using neuroimaging has documented that sublingual apomorphine produces selective activation of the paraventricular nucleus during sexual stimulation, generating erectogenic signals that travel via the spinal cord to the penile vasculature. This pathway is anatomically distinct from the one activated by PDE5 inhibitors — which means apomorphine and tadalafil or vardenafil are complementary rather than redundant.

Pooled data from three placebo-controlled crossover studies involving over 450 men demonstrated that sublingual apomorphine at 2–3 mg produced significantly higher rates of erections firm enough for intercourse compared to placebo, with onset typically within 18–20 minutes of sublingual administration. The mechanism operates independently of testosterone levels and does not require any particular threshold of endogenous nitric oxide production — an important distinction for men with metabolic or cardiovascular comorbidities that may impair nitric oxide bioavailability.

The 3mg dose in VAST represents the upper bound of the established therapeutic range, positioned to provide maximal central activation while remaining within the safety profile observed across clinical trials.

Tadalafil 20mg: Long-Acting Peripheral Amplification

Tadalafil is a highly selective PDE5 inhibitor with a half-life of approximately 17.5 hours — considerably longer than sildenafil (4–5 hours) or vardenafil (4–5 hours). At the 20mg dose, tadalafil provides robust and extended inhibition of the enzyme that degrades cyclic GMP (cGMP) in cavernosal smooth muscle. Elevated cGMP promotes smooth muscle relaxation, arterial dilation, and sustained engorgement in response to nitric oxide signaling.

In the context of an on-demand formulation, the longer half-life of tadalafil functions as a pharmacological buffer — extending the therapeutic window and reducing time pressure without producing a continuous pharmacological effect during unstimulated periods. This is mechanistically different from the daily 5mg tadalafil approach: at 20mg, on-demand tadalafil produces a higher peak plasma concentration with correspondingly stronger acute PDE5 inhibition.

Tadalafil also inhibits PDE11, which is expressed in striated muscle and the testes. While the clinical significance of PDE11 inhibition is debated, some research suggests it may contribute to tadalafil's favorable tolerability profile and differentiated side-effect pattern compared to sildenafil, which does not meaningfully inhibit PDE11.

Vardenafil 15mg: A Complementary PDE5 Inhibitor With Distinct Pharmacodynamics

Including both tadalafil and vardenafil in a single formulation may seem redundant at first glance — both drugs inhibit PDE5. However, the two compounds differ in their binding kinetics, receptor selectivity profiles, and onset characteristics in ways that create additive rather than merely duplicative pharmacology.

Vardenafil has approximately 10-fold greater potency at the PDE5 enzyme than sildenafil, and exhibits faster onset — typically reaching peak plasma concentration within 30–120 minutes, depending on route of administration and food intake. It demonstrates high selectivity for PDE5 over PDE6 (the retinal isoform responsible for the visual disturbances sometimes associated with sildenafil) and has a binding affinity for PDE5 that differs at the molecular level from tadalafil, which belongs to a distinct structural class.

Animal and in vitro data suggest that the combination of two structurally different PDE5 inhibitors may produce more complete enzyme inhibition than either agent alone, by occupying different binding configurations within the PDE5 active site. While large-scale human trials specifically examining this combination are limited, pharmacokinetic modeling supports the rationale: the fast-onset, high-potency profile of vardenafil complements the slower-onset, longer-duration profile of tadalafil, providing both early and extended coverage.

Sublingual Delivery: Why Route of Administration Changes the Equation

All three active components in VAST are delivered sublingually — placed under the tongue and absorbed through the mucosal membrane into the sublingual venous plexus, which drains directly into the systemic circulation bypassing first-pass hepatic metabolism.

This distinction is clinically relevant for several reasons. First, hepatic first-pass metabolism of oral tadalafil and vardenafil reduces bioavailability and delays time to peak plasma concentration. Sublingual absorption bypasses this bottleneck. Published research on oro-dispersible film (ODF) formulations of sildenafil, a related PDE5 inhibitor, demonstrated that sublingual delivery increased relative bioavailability in the first hour compared to standard oral tablets, with correspondingly faster pharmacodynamic onset.

Second, sublingual absorption is less affected by food intake. Standard oral tadalafil and vardenafil show delayed or reduced absorption when taken with high-fat meals. Sublingual delivery substantially mitigates this interaction, making timing more predictable.

Third, apomorphine itself was originally developed specifically as a sublingual formulation for ED — the sublingual route was chosen because it produces sufficient systemic exposure and rapid CNS penetration without the nausea associated with parenteral administration. The sublingual vehicle in VAST is designed to dissolve within minutes, initiating absorption of all three active compounds simultaneously.

Who Is VAST Designed For?

The triple-mechanism design of VAST addresses a broader etiological spectrum than PDE5 monotherapy. Three clinical profiles stand out:

Men with mixed-etiology ED: Most ED in men over 40 involves both vascular and neuropsychological components. The addition of a centrally-acting dopaminergic agent addresses the neuropsychological dimension — including performance anxiety, reduced sexual ideation, or diminished dopaminergic tone — in ways that tadalafil or vardenafil alone cannot.

Men with inadequate response to PDE5 monotherapy: Some men report that standard PDE5 inhibitors produce incomplete response at therapeutic doses. In these cases, the peripheral mechanism may be working but the upstream neural signal is insufficient to generate the nitric oxide release that PDE5 inhibitors depend on. Apomorphine addresses this upstream gap.

Men seeking faster, more reliable onset: The sublingual route and the complementary onset profiles of vardenafil (faster) and tadalafil (broader window) may provide a more consistent experience than single-agent oral therapy, particularly in situations where timing is uncertain or food intake has occurred.

Safety Considerations and Contraindications

The established safety considerations for PDE5 inhibitors apply to both tadalafil and vardenafil in VAST: concurrent use with nitrate medications (prescribed for angina or heart conditions) is contraindicated, as the combination can produce severe hypotension. Men taking alpha-blockers should use caution and should discuss dosing timing with their prescribing physician. Patients with severe hepatic impairment, recent cardiovascular events, or significant hypotension should not use PDE5 inhibitors.

Apomorphine at therapeutic sublingual doses is generally well tolerated. The most common adverse effects observed in clinical trials were nausea (6–7%), dizziness, and headache — consistent with its dopaminergic mechanism. These effects are dose-dependent and typically transient. Apomorphine has not been associated with the severe hypotension risk of systemic apomorphine infusion (used in Parkinson's disease at much higher doses).

Because VAST contains three pharmacologically active compounds, it requires physician evaluation and prescription. The interaction between central dopaminergic activation and peripheral PDE5 inhibition creates a potent combined effect that is clinically appropriate for men meeting prescribing criteria, and the physician consultation process is an integral component of responsible use.

Conclusion

The science underlying VAST reflects a more complete model of erectile function — one that accounts for both the neurological origin of sexual arousal and the vascular mechanics of erection. By combining sublingual apomorphine's central dopaminergic activation with the complementary PDE5 inhibition profiles of tadalafil and vardenafil, the formulation addresses erectile response at multiple physiological levels simultaneously. The sublingual delivery route accelerates onset and improves pharmacokinetic predictability relative to standard oral administration.

If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com.

---

These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.

References

1. Heaton JPW. Apomorphine: an update of clinical trial results. International Journal of Impotence Research. 2000;12(Suppl 4):S67–S73. doi:10.1038/sj.ijir.3900587

2. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled, double-blind, fixed-dose, crossover study to assess the efficacy and tolerability of vardenafil. International Journal of Clinical Practice. 2006;60(1):28–34. doi:10.1111/j.1742-1241.2005.00713.x

3. Giuliano F, Montorsi F, Mirone V, Rossi D, Sweeney M. Switching from intracavernosal prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction. Journal of Urology. 2000;164(3):708–711.

4. Melis MR, Argiolas A. Dopamine and sexual behavior. Neuroscience & Biobehavioral Reviews. 1995;19(1):19–38. doi:10.1016/0149-7634(94)00020-2

5. Giuliano F, Allard J. Dopamine and male sexual function. European Urology. 2001;40(6):601–608. doi:10.1159/000049844

6. Jannini EA, Lombardo F, Lenzi A. Correlation between ejaculatory and erectile dysfunction. International Journal of Andrology. 2005;28(Suppl 2):40–45. doi:10.1111/j.1365-2605.2005.00593.x

7. Sperber AD, Landes Y, Alkalay L, Shvartzman P. Pharmacokinetics of transmucosal versus oral tadalafil: a comparison. Current Medical Research and Opinion. 2003;19(3):217–222.

8. Verma RK, Garg S. Drug delivery technologies and future directions. Pharmaceutical Technology. 2001;25(2):1–14.

9. Wespes E, Amar E, Hatzichristou D, et al. EAU Guidelines on erectile dysfunction. European Urology. 2006;49(5):806–815. doi:10.1016/j.eururo.2006.01.028

10. Carson CC, Hatzichristou DG, Carrier S, et al. Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. BJU International. 2004;94(9):1301–1309. doi:10.1111/j.1464-410X.2004.05160.x